Biblio
Export 796 results:
Author Title Type [ Year
Filters: First Letter Of Keyword is P [Clear All Filters]
“Neuronal basis of age-related working memory decline.”, Nature, vol. 476, no. 7359, pp. 210-3, 2011.
, “Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders.”, Ann Neurol, vol. 70, no. 4, pp. 532-40, 2011.
, “Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders.”, Ann Neurol, vol. 70, no. 4, pp. 532-40, 2011.
, “Report of the task force on designing clinical trials in early (predementia) AD.”, Neurology, vol. 76, no. 3, pp. 280-6, 2011.
, “Report of the task force on designing clinical trials in early (predementia) AD.”, Neurology, vol. 76, no. 3, pp. 280-6, 2011.
, “Report of the task force on designing clinical trials in early (predementia) AD.”, Neurology, vol. 76, no. 3, pp. 280-6, 2011.
, “Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration.”, Proc Natl Acad Sci U S A, vol. 108, no. 14, pp. 5819-24, 2011.
, “Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”, Alzheimers Dement, vol. 7, no. 3, pp. 280-92, 2011.
, “Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease.”, Neurology, vol. 76, no. 17, pp. 1485-91, 2011.
, “APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.”, Ann Neurol, vol. 67, no. 1, pp. 122-31, 2010.
, “APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.”, Ann Neurol, vol. 67, no. 1, pp. 122-31, 2010.
, “APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.”, Ann Neurol, vol. 67, no. 1, pp. 122-31, 2010.
, “Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways.”, Proc Natl Acad Sci U S A, vol. 107, no. 28, pp. 12698-703, 2010.
, “Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease.”, Nature, vol. 467, no. 7311, pp. 95-8, 2010.
, “Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease.”, Nature, vol. 467, no. 7311, pp. 95-8, 2010.
, “Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease.”, Nature, vol. 467, no. 7311, pp. 95-8, 2010.
, “Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease.”, Nature, vol. 467, no. 7311, pp. 95-8, 2010.
, “Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease.”, PLoS One, vol. 5, no. 11, p. e13950, 2010.
, “Memory impairment in transgenic Alzheimer mice requires cellular prion protein.”, J Neurosci, vol. 30, no. 18, pp. 6367-74, 2010.
, “Memory impairment in transgenic Alzheimer mice requires cellular prion protein.”, J Neurosci, vol. 30, no. 18, pp. 6367-74, 2010.
, “Tau in Alzheimer disease and related tauopathies.”, Curr Alzheimer Res, vol. 7, no. 8, pp. 656-64, 2010.
,